{"entity":{"id":"nct07808151","kind":"trial","name":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","aka":[],"tldr":"A phase 2 trial of pembrolizumab in colorectal cancer, run by Solstice Oncology, Inc., not yet recruiting.","summary":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer is a phase 2, randomised interventional study registered as NCT07808151 by Solstice Oncology, Inc., with a registry enrolment figure of 100 participants, started 2026-09-30 and due to reach its primary completion in 2029-09-30. Interventions recorded: Pembrolizumab; Porustobart. Conditions listed: Colon Cancer; Microsatellite Stable (MSS) Colon Cancer; Proficient Mismatch Repair (pMMR) Colon Cancer. Primary outcome: Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR). Colorectal eligibility wording from the registry: \"Adenocarcinoma of the colon (rectosigmoid considered non-rectal); pMMR/MSS status\". Sites: Belgium, Italy, Netherlands, Spain, United Kingdom, United States. United Kingdom sites listed: 5. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07808151","url":"https://clinicaltrials.gov/study/NCT07808151"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Investigator Site (Aberdeen); Investigator Site (Cardiff); Investigator Site (Glasgow); Investigator Site (Leeds); Investigator Site (London)."],"nct":"NCT07808151","phase":"2","setting":"A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer","sponsor":"Solstice Oncology, Inc.","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07808151/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}